Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.32 |
| ▸ | SLC2A3 | P11169 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30225254 | 1.00 | ACACB (0.36) | ACACBSLC2A1SLC2A3HDAC1HDAC8 | |
| SCHEMBL23976502 | 0.92 | SLC2A1 (0.34) | ACACBSLC2A1SLC2A3HDAC1HDAC8 | |
| SCHEMBL30225239 | 0.88 | SLC2A1 (0.33) | ACACBSLC2A1SLC2A3 | |
| SCHEMBL26229008 | 0.86 | HDAC1 (0.35) | SLC2A1SLC2A3HDAC1HDAC8HDAC6 | |
| SCHEMBL30118568 | 0.86 | HDAC1 (0.35) | ACACBSLC2A1SLC2A3HDAC1HDAC8 | |
| SCHEMBL23975994 | 0.86 | HDAC1 (0.35) | ACACBSLC2A1SLC2A3HDAC1HDAC8 | |
| SCHEMBL24702214 | 0.84 | SLC2A1 (0.31) | ACACBSLC2A1SLC2A3 | |
| SCHEMBL24702435 | 0.84 | SLC2A1 (0.30) | SLC2A1SLC2A3 | |
| SCHEMBL30118714 | 0.81 | MEN1 (0.37) | SLC2A1SLC2A3HDAC1HDAC8HDAC6 | |
| SCHEMBL23975778 | 0.81 | MEN1 (0.37) | SLC2A1SLC2A3HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2021222363-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | ACACB 3237/4885SLC2A1 153/4885SLC2A3 219/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | ACACB 3165/4885SLC2A1 285/4885SLC2A3 315/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | ACACB 3165/4885SLC2A1 285/4885SLC2A3 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.